Drugs / memory-like natural killer cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06158828 | Nov 2024 → Sep 2028 expected | acute myeloid leukemia by FAB classification, childhood acute myeloid leukemia | Washington University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | memory-like natural killer cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06158828 ↗ |
| Modality | Cell therapy | “The ML NK cells (dose: max capped at 20 x 10\^6/kg recipient weight, minimum dose allowed is 0.5 x 10\^6/kg recipient weight) will be infused on Day +7.” NCT06158828 ↗ |